Gritstone
Location: United States, California, Emeryville
Employees: 51-200
Total raised: $194.7M
Founded date: 2015
Investors 7
| Date | Name | Website |
| - | Aberdare V... | aberdare.c... |
| - | PFM Health... | pfmhealths... |
| - | LAV | lavfund.co... |
| - | The Column... | thecolumng... |
| - | Altitude L... | altitudels... |
| - | Bay City C... | baycitycap... |
| - | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.09.2017 | Series B | $92.7M | - |
| 20.10.2015 | - | $102M | - |
Mentions in press and media 20
| Date | Title | Description |
| 15.04.2025 | Northern Gritstone: Fueling the Future of Life Sciences and DeepTech in the North of England | In the heart of the North of England, a financial powerhouse is emerging. Northern Gritstone, an investment firm rooted in the rich soil of academia, has just secured a significant £50 million in funding. This is not just a number; it’s a b... |
| 14.04.2025 | Northern Gritstone: £50 Million Funding Raised To Invest In Life Sciences Companies | Northern Gritstone is a deep-tech and life sciences investment firm founded with the support of the Universities of Sheffield, Leeds, and Manchester. The firm has announced its latest fundraise of £50 million from leading institutional inve... |
| 10.04.2025 | Investment firm Northern Gritstone secures €58 million for life sciences and DeepTech | Manchester-based Northern Gritstone, the life sciences and DeepTech investment firm, has announced its latest fundraise of €58 million from leading institutional investors bringing its total permanent capital to €422 million. €40 million of... |
| 17.12.2018 | Gritstone Oncology showcases AI-based platform’s neoantigen-discovery chops | The company used three datasets to validate EDGE as a machine learning-based system for identifying neoantigens, which are cancer cell proteins to which the immune system has not been previously exposed. “Neoantigens are critical targets of... |
| 26.01.2018 | Heptares co-founder Fiona Marshall to lead Merck's London research hub; Ablynx appoints Robert Friesen as new CFO | Fiona Marshall → In a boost to its planned $1.3 billion UK drug research hub and headquarters, Merck has recruited the noted British scientist and biotech exec Fiona Marshall to the top job at the center, which is expected t... |
| 23.01.2018 | Incyte tries to fend off TRC's mini-tender offer to investors; Gritstone Oncology scoops Actelion CFO Jean-Marc Bellemin | → Incyte $INCY is counting on its investors to protect 0.71% — or 1,500,000 shares — of its common stock, from Canada’s TRC Capital, which is out to buy them at a discount price. The investment firm promised $88.88 per share in ... |
| 08.09.2017 | Term Sheet — Friday, September 8 | HOT TAKES Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop To the reader who said he would invest the $100K in “a massage therapy place as the Bay area has so much stress” — trust me, N... |
| 07.09.2017 | Gritstone Oncology Pulls In $92.7M Series B | EMERYVILLE, CA, Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the successful completion of a $92.7 million Series B preferred stock financing. >> Click here for more funding data o... |
| 07.09.2017 | Gritstone Oncology Secures $92.7M in Series B Financing | Gritstone Oncology, an Emeryville, Calif.-based personalized cancer immunotherapy company, completed a $92.7m Series B financing. The round was led by new investor Lilly Asia Ventures, with participation from GV (formerly Google Ventures), ... |
| 05.05.2017 | Merck vet Robert Plenge moves to Celgene, Gritstone recruits a Genentech star and more | → ImCheck not only has a recent €20 million Series A under its belt, the biotech also named Pierre d’Epenoux as it Chief Executive Officer. D’Epenoux’s previous gigs include head of strategy and business development a... |
Show more